Free tool · No account
Clinical trials for melanoma
Melanoma has been a proving ground for immunotherapy, and many trials build on that. Some are limited to tumors with a BRAF mutation, so that detail is worth including if you have it.
464 recruiting trials. Showing a sample.
- recruitingNANCT06753136
Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
This is an monocenter, single arm, clinical investigation that evaluate the impact of the method on the objective response rate (ORR) of visceral lesions undergoing electrochemotherapy. Electrochemotherapy is a well-defined method for the treatment of cutaneous and subcutaneou...
Listed by the study for Melanoma. Record updated 2026-04-13.
Sponsored by Istituto Oncologico Veneto IRCCSFull details on ClinicalTrials.gov → - recruitingPhase 2NCT04594187
Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma
This phase II trial seeks to determine the role of nodal radiation therapy after sentinel lymph node biopsy (SLNB) for patients with high risk sentinel lymph node positive melanoma who are planned for immunotherapy without completion lymph node dissection. Prior studies of pat...
Listed by the study for Melanoma. Record updated 2026-08-10.
Sponsored by M.D. Anderson Cancer CenterFull details on ClinicalTrials.gov → - recruitingPhase 3NCT07804186
Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma
This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)
Listed by the study for Uveal Melanoma. Record updated 2026-11-12.
Sponsored by IDEAYA BiosciencesFull details on ClinicalTrials.gov → - recruitingPhase 2NCT07040280
Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma
This phase II trial tests how well sulforaphane works in preventing melanoma in patients with multiple atypical moles (nevi) and a prior history of melanoma. Patients with a history of melanoma and multiple atypical nevi are at a significantly increased risk of developing addi...
Listed by the study for Clinical Stage 0 Cutaneous Melanoma AJCC v8. Record updated 2026-09-15.
Sponsored by ECOG-ACRIN Cancer Research GroupFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT04787042
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination with pembrolizumab. A Phase 2 monother...
Listed by the study for Melanoma. Record updated 2024-11-15.
Sponsored by Simcha IL-18, Inc.Full details on ClinicalTrials.gov → - recruitingPhase 1NCT07634380
Sitagliptin With Pembro in RCC and Melanoma
This study is testing whether adding the drug sitagliptin to the standard immunotherapy pembrolizumab is safe and may help people with advanced melanoma or advanced renal cell carcinoma (kidney cancer) whose cancer has stopped responding to prior PD-1 or PD-L1 immunotherapy. ...
Listed by the study for Advanced Melanoma. Record updated 2026-07-30.
Sponsored by Fernando Maciel BarbosaFull details on ClinicalTrials.gov → - recruitingPhase 1NCT04697576
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
This phase I trial investigates the effects of influenza vaccine in treating patients with stage I-IV melanoma. While intramuscular administration of influenza vaccine provides immunization against the influenza virus, giving influenza vaccine directly into the tumor (intrales...
Listed by the study for Clinical Stage I Cutaneous Melanoma AJCC v8. Record updated 2026-07-13.
Sponsored by Carlo ContrerasFull details on ClinicalTrials.gov → - recruitingNANCT05649683
Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibitors
Checkpoint inhibitor such as anti-CTLA-4 and anti-PD-1 are known to block inhibitory signals and increase the immune antimutoral response. Nivolumab and Ipilimumab association is considered as a more efficient immunotherapy to treat advanced melanoma. This combined immunothera...
Listed by the study for Melanoma (Skin). Record updated 2024-06-04.
Sponsored by Centre Hospitalier Universitaire de NiceFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06887088
Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases
Brain metastases in patients with advanced and metastatic melanoma are a frequent complication and a significant cause of morbidity and mortality in this patient population. As the incidence of brain metastases continues to increase in patients with metastatic melanoma, it is ...
Listed by the study for Melanoma BRAF V600E/K Mutated. Record updated 2025-10-01.
Sponsored by Grupo Español Multidisciplinar de MelanomaFull details on ClinicalTrials.gov → - recruitingNCT06861023
Review of the Literature and Serie of Patients Who Underwent Reconstruction After Wide Local Excision of Nail Apparatus for Melanoma
Melanomas of the nail bed are often diagnosed at the locally advanced stage. The standard treatment was amputation of the finger or toe, but it has now been established that enlarged excision of the nail plate is sufficient under certain conditions. Reconstruction of the nail ...
Listed by the study for Melanoma. Record updated 2025-03-06.
Sponsored by Centre Hospitalier Universitaire de NiceFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-11-14. Study sponsors write and update their own records there, including the recruitment status shown here, and the U.S. government does not review or approve every study listed. A trial showing up here is not a recommendation and not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- KeptWell does not opt in to model training. OpenAI and Anthropic do not use API inputs or outputs to train their models by default.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this melanoma trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. A listing here is not a recommendation, and the U.S. government does not review or approve every study on ClinicalTrials.gov. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily, with the retrieval date shown under the list. Each study record is written and kept up to date by that study's own sponsor, so the recruitment status is what the sponsor last reported. Each result links to the full, live record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
We'll email you a secure sign-in link. It works whether you're new here or already have an account.